Margo R. Roberts is CSO at Kite Pharma, Inc. (KITE). They have made 6 open-market trades across 1 company since 2015, most recently 2016-03-15.
CIK 0001510580
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KITE | 18,730 | $3.4M |
Shares reported on the most recent Form 4, priced at the 2016-03-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KITE | SELL | 2016-03-15 | 2016-03-17 | $45.09 | $352K | -1.5% | +6.8% | +17.1% |
| KITE | SELL | 2016-03-15 | 2016-03-17 | $45.23 | $385K | -1.5% | +6.8% | +17.1% |
| KITE | SELL | 2016-02-17 | 2016-02-19 | $45.06 | $863K | +9.9% | -6.4% | -7.1% |
| KITE | SELL | 2016-02-12 | 2016-02-16 | $64.16 | $1.2M | +5.3% | -0.9% | +0.1% |
| KITE | SELL | 2016-01-15 | 2016-01-19 | $55.22 | $339K | -11.8% | -13.3% | -11.0% |
| KITE | SELL | 2016-01-15 | 2016-01-19 | $55.31 | $253K | -11.8% | -13.3% | -11.0% |
| KITE | SELL · 10b5-1 | 2015-12-15 | 2015-12-17 | $63.76 | $392K | -16.7% | -9.2% | -27.0% |
| KITE | SELL · 10b5-1 | 2015-11-16 | 2015-11-18 | $78.16 | $480K | -16.7% | +2.4% | -25.8% |
| KITE | SELL · 10b5-1 | 2015-10-15 | 2015-10-19 | $62.57 | $385K | -16.7% | +2.4% | -9.2% |
| KITE | SELL · 10b5-1 | 2015-09-15 | 2015-09-17 | $64.33 | $395K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-08-17 | 2015-08-19 | $60.90 | $374K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-07-15 | 2015-07-23 | $71.89 | $1.6M | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-06-15 | 2015-06-17 | $56.99 | $491K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-05-15 | 2015-05-19 | $50.17 | $433K | -16.7% | +2.4% | +2.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.